ArticleFrontiers in public health2026
Transcriptomics and Mendelian randomization studies reveal the critical role of Stanniocalcin-2 in linking perfluorinated compound-exposure to colorectal cancer.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal carcinoma (CRC) represents a major gastrointestinal malignancy with substantial global incidence, marked by elevated morbidity and mortality rates. Despite advancements in treatment, there is still considerable variation in prognosis, particularly with high recurrence rates, emphasizing the need for more precise prognostic tools. The present study is aimed at identifying central prognostic biomarkers linked to perfluorinated compound (PFCs) exposure and construct a prognostic risk model for CRC based on transcriptomic data. We analyzed transcriptome data from 638 CRC samples and 51 normal control samples from The Cancer Genome Atlas (TCGA) database, then identified a total of 3,230 PFC-associated genes. Candidate genes related to CRC prognosis were found by analyzing differences in gene expression, doing functional enrichment, and building a protein-protein interaction (PPI) network. We built a LASSO model with PRAME, CDKN2A, and STC2 and checked it using Kaplan-Meier analysis and ROC curves over time, while STC2 was further identified as the key mediator linking PFC exposure to CRC risk based on Mendelian randomization and experimental validation. This model could put patients into high-risk or low-risk groups, which gives doctors a new tool to plan personalized treatments. We also checked the immune setting, tumor mutation load, and likely response to immunotherapy, which further proved the model's usefulness in the clinic. A Mendelian randomization (MR) analysis in two steps showed that higher levels of genetic risk for Perfluorooctanoic acid (PFOA) and Perfluorooctanesulfonic acid (PFOS) exposure raised CRC risk. STC2 was found to partly explain the mediator from PFOA to CRC, making up about 8.6% of the overall effect. We ran sensitivity checks, and the results still held, which means these cause-and-effect findings are strong. Finally,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.